Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Medtronic's tablet-controlled pain device

The Intellis system can be programmed via a Samsung's Galaxy S2

Medtronic Samsung

Medtronic has won US approval for, and launched, a pain management implant that can be remotely controlled by a Samsung tablet.

The Intellis system treats chronic pain via neurostimulation, the level of which can be adjusted wirelessly by the Samsung Galaxy Tab S2.

Marshall Stanton, president of Medtronic's Pain Therapies division, said: "Drawing upon our 40-year legacy in SCS, the launch of the Intellis platform isn't just about a new device, but about combining cutting edge hardware with optimal therapy.”

Intellis is the world's smallest fully implantable SCS (spinal cord stimulation) neurostimulator and can also track daily activities, body positions and therapy usage to provide physicians with data on a patient’s mobility and progress.

Dr Dave Rhew, chief medical officer and head of healthcare and fitness at Samsung Electronics America, said: "We are excited to partner with Medtronic in their aim to simplify programming, and streamline therapy management with the Intellis platform.

"Samsung's Galaxy tablets-secured by the HIPAA-ready Samsung Knox mobile security platform-will support future Medtronic therapies and over the air (OTA) software upgrades to ensure clinicians using Intellis have access to the most up-to-date solutions."

The two firms have previously worked together in diabetes, to develop a range of solutions to enhance management of the condition.

Article by
Dominic Tyer

21st September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics